China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. It offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. The company also provides bone peptide, oxytocin, heparin sodium, and posterior pituitary injection produ… Read more
China Resources Boya Bio pharmaceutical Group Co Ltd (300294) - Net Assets
Latest net assets as of September 2025: CN¥7.67 Billion CNY
Based on the latest financial reports, China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has net assets worth CN¥7.67 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.73 Billion) and total liabilities (CN¥1.05 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.67 Billion |
| % of Total Assets | 87.92% |
| Annual Growth Rate | 34.69% |
| 5-Year Change | 78.6% |
| 10-Year Change | 292.42% |
| Growth Volatility | 56.11 |
China Resources Boya Bio pharmaceutical Group Co Ltd - Net Assets Trend (2008–2024)
This chart illustrates how China Resources Boya Bio pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for China Resources Boya Bio pharmaceutical Group Co Ltd (2008–2024)
The table below shows the annual net assets of China Resources Boya Bio pharmaceutical Group Co Ltd from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.49 Billion | +2.28% |
| 2023-12-31 | CN¥7.32 Billion | +0.49% |
| 2022-12-31 | CN¥7.28 Billion | +5.26% |
| 2021-12-31 | CN¥6.92 Billion | +65.07% |
| 2020-12-31 | CN¥4.19 Billion | +5.11% |
| 2019-12-31 | CN¥3.99 Billion | +5.78% |
| 2018-12-31 | CN¥3.77 Billion | +51.77% |
| 2017-12-31 | CN¥2.48 Billion | +16.51% |
| 2016-12-31 | CN¥2.13 Billion | +11.74% |
| 2015-12-31 | CN¥1.91 Billion | +106.52% |
| 2014-12-31 | CN¥923.93 Million | +9.13% |
| 2013-12-31 | CN¥846.62 Million | +12.64% |
| 2012-12-31 | CN¥751.60 Million | +186.14% |
| 2011-12-31 | CN¥262.67 Million | +33.04% |
| 2010-12-31 | CN¥197.44 Million | +20.03% |
| 2009-12-31 | CN¥164.49 Million | +157.87% |
| 2008-12-31 | CN¥63.79 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to China Resources Boya Bio pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 29978.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.67 Billion | 35.60% |
| Common Stock | CN¥504.25 Million | 6.73% |
| Other Comprehensive Income | CN¥258.33 Million | 3.45% |
| Other Components | CN¥4.06 Billion | 54.21% |
| Total Equity | CN¥7.49 Billion | 100.00% |
China Resources Boya Bio pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of China Resources Boya Bio pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Desay Battery Technology Co Ltd
SHE:000049
|
$768.09 Million |
|
Amerant Bancorp Inc.
NYSE:AMTB
|
$768.19 Million |
|
Servyou Software Group Co Ltd
SHG:603171
|
$768.21 Million |
|
Chongqing Taiji Industry Group Co Ltd
SHG:600129
|
$768.31 Million |
|
Butterfly Network Inc
NYSE:BFLY
|
$767.91 Million |
|
Jiangsu Shemar Electric Co Ltd
SHG:603530
|
$767.85 Million |
|
PixArt Imaging
TWO:3227
|
$767.78 Million |
|
Pantoro Gold Ltd
AU:PNR
|
$767.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in China Resources Boya Bio pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,319,750,577 to 7,487,150,950, a change of 167,400,373 (2.3%).
- Net income of 396,991,594 contributed positively to equity growth.
- Dividend payments of 232,409,473 reduced retained earnings.
- Other comprehensive income increased equity by 2,363,203.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥396.99 Million | +5.3% |
| Dividends Paid | CN¥232.41 Million | -3.1% |
| Other Comprehensive Income | CN¥2.36 Million | +0.03% |
| Other Changes | CN¥455.05K | +0.01% |
| Total Change | CN¥- | 2.29% |
Book Value vs Market Value Analysis
This analysis compares China Resources Boya Bio pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 66.05x to 1.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.31 | CN¥20.72 | x |
| 2009-12-31 | CN¥0.75 | CN¥20.72 | x |
| 2010-12-31 | CN¥0.77 | CN¥20.72 | x |
| 2011-12-31 | CN¥1.03 | CN¥20.72 | x |
| 2012-12-31 | CN¥2.36 | CN¥20.72 | x |
| 2013-12-31 | CN¥2.33 | CN¥20.72 | x |
| 2014-12-31 | CN¥2.53 | CN¥20.72 | x |
| 2015-12-31 | CN¥5.43 | CN¥20.72 | x |
| 2016-12-31 | CN¥7.85 | CN¥20.72 | x |
| 2017-12-31 | CN¥6.05 | CN¥20.72 | x |
| 2018-12-31 | CN¥8.76 | CN¥20.72 | x |
| 2019-12-31 | CN¥9.18 | CN¥20.72 | x |
| 2020-12-31 | CN¥9.64 | CN¥20.72 | x |
| 2021-12-31 | CN¥15.66 | CN¥20.72 | x |
| 2022-12-31 | CN¥14.25 | CN¥20.72 | x |
| 2023-12-31 | CN¥14.49 | CN¥20.72 | x |
| 2024-12-31 | CN¥14.85 | CN¥20.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently China Resources Boya Bio pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.30%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.88%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.12x
- Recent ROE (5.30%) is below the historical average (12.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 17.00% | 11.88% | 0.60x | 2.37x | CN¥4.41 Million |
| 2009 | 19.14% | 26.29% | 0.38x | 1.92x | CN¥15.03 Million |
| 2010 | 25.31% | 35.24% | 0.48x | 1.50x | CN¥30.23 Million |
| 2011 | 24.83% | 33.41% | 0.59x | 1.26x | CN¥38.97 Million |
| 2012 | 10.00% | 33.07% | 0.29x | 1.03x | CN¥-14.18K |
| 2013 | 10.40% | 33.60% | 0.24x | 1.27x | CN¥3.19 Million |
| 2014 | 12.14% | 23.80% | 0.43x | 1.19x | CN¥18.34 Million |
| 2015 | 8.10% | 27.95% | 0.25x | 1.17x | CN¥-35.68 Million |
| 2016 | 13.00% | 28.74% | 0.39x | 1.16x | CN¥62.70 Million |
| 2017 | 14.70% | 25.65% | 0.38x | 1.51x | CN¥114.01 Million |
| 2018 | 12.66% | 19.65% | 0.47x | 1.37x | CN¥98.71 Million |
| 2019 | 10.89% | 14.65% | 0.55x | 1.34x | CN¥34.97 Million |
| 2020 | 6.33% | 10.35% | 0.49x | 1.26x | CN¥-150.73 Million |
| 2021 | 5.05% | 13.00% | 0.35x | 1.12x | CN¥-338.38 Million |
| 2022 | 6.01% | 15.67% | 0.34x | 1.12x | CN¥-286.37 Million |
| 2023 | 3.24% | 8.95% | 0.34x | 1.07x | CN¥-494.51 Million |
| 2024 | 5.30% | 22.88% | 0.21x | 1.12x | CN¥-351.72 Million |
Industry Comparison
This section compares China Resources Boya Bio pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| China Resources Boya Bio pharmaceutical Group Co Ltd (300294) | CN¥7.67 Billion | 17.00% | 0.14x | $768.06 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |